Pei Dong, Zhu Fang, Chen Xiaofeng, Qian Jing, He Shaohua, Qian Yingying, Shen Hua, Liu Yiqian, Xu Jiali, Shu Yongqian
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300#, Nanjing 210029, China.
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300#, Nanjing 210029, China.
Biomed Pharmacother. 2014 Mar;68(2):213-7. doi: 10.1016/j.biopha.2014.01.008. Epub 2014 Feb 7.
Gastric cancer (GC) has a high morbidity worldwide each year especially in China and advanced GC is well known with poor prognosis, for which surgical resection combine adjuvant chemotherapy is the optimal choice for therapy. Leukocyte is an important index during the treatment for its influence on drugs' dosage and tolerance. Therefore, peripheral blood leukocyte and its subsets during adjuvant chemotherapy may have great clinical value for predicting prognostic. In this retrospective study, we showed the distribution of white blood cell and its subsets in the baseline period before adjuvant chemotherapy in 399 patients who underwent radical resection for advanced GC from January 1, 2008 to August 31, 2012. We investigated the relationship between leukocyte count and overall survival (OS) as well as disease-free survival (DFS). In these patients, females were more likely to have less white blood cells after operation (P=0.016). Patients with pre-chemotherapy leukocyte count less than 4×10(9)/L got worse DFS (P=0.028) and OS (P=0.016). In multivariate analysis, tumor size ≥ 6cm (P=0.033), TNM stage IV (P=0.024), vascular or nerval invasion (P=0.005) and leukocyte count less than 4.0×10(9)/L (P=0.019) was associated with poor DFS. TNM stage IV (P=0.008), vascular or nerval invasion (P=0.001) and lower leukocyte count (P=0.045) were independent risk factors for poor OS. Taken together, our findings suggest that pre-adjuvant chemotherapy peripheral blood leukocyte count correlates with clinical outcome of patients with advanced GC after radical resection.
胃癌(GC)在全球每年的发病率都很高,尤其是在中国,晚期胃癌的预后众所周知很差,手术切除联合辅助化疗是最佳治疗选择。白细胞是治疗期间的一个重要指标,因为它会影响药物剂量和耐受性。因此,辅助化疗期间的外周血白细胞及其亚群对于预测预后可能具有重要的临床价值。在这项回顾性研究中,我们展示了2008年1月1日至2012年8月31日期间399例行晚期GC根治性切除患者在辅助化疗前基线期白细胞及其亚群的分布情况。我们研究了白细胞计数与总生存期(OS)以及无病生存期(DFS)之间的关系。在这些患者中,女性术后白细胞减少的可能性更大(P = 0.016)。化疗前白细胞计数低于4×10⁹/L的患者DFS更差(P = 0.028),OS也更差(P = 0.016)。多因素分析显示,肿瘤大小≥6cm(P = 0.033)、TNM分期IV期(P = 0.024)、血管或神经侵犯(P = 0.005)以及白细胞计数低于4.0×10⁹/L(P = 0.019)与DFS不良相关。TNM分期IV期(P = 0.008)、血管或神经侵犯(P = 0.001)以及较低的白细胞计数(P = 0.045)是OS不良的独立危险因素。综上所述,我们的研究结果表明,辅助化疗前外周血白细胞计数与晚期GC根治术后患者的临床结局相关。